Z
Zhengxu (Shanghai) Biotechnology
Pioneering next-gen gene editing therapies with proprietary base editing technology
About Zhengxu (Shanghai) Biotechnology
CorrectSequence Therapeutics is a clinical-stage biotech company specializing in advanced gene editing therapies. Utilizing its proprietary transformer Base Editor (tBE), the company aims to develop next-generation solutions for severe diseases. The management and R&D teams boast over a decade of industry experience, with more than 40% holding master's degrees. CorrectSequence Therapeutics focuses on biotechnology innovation, research, and development to provide efficient, reliable, and safe solutions for unmet medical needs. The company leverages recent advances in chemical modifications of guide RNA, mRNA, and donor templates for CRISPR-mediated genome editing. Their technology induces precise base substitutions, combining two key components—effector and locator—to achieve targeted genome editing. CorrectSequence Therapeutics serves clients in the healthcare and pharmaceutical sectors, operating primarily in the biotech market. The business model revolves around developing and commercializing gene editing therapies, generating revenue through clinical trials and partnerships.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2020
- Headquarters
- Huangpu, China
- Employees
- 9
- Open positions
- None listed
- Dealroom signal
- 48.4/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
- Links
- Website
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES AOther financing | Aug 2024 | $14M | $248M | Lilly Asia Ventures · New Alliance Capital · FuTeng Capital · Boyu Capital | ↗ |
| FundingOther financing | Jan 2023 | $0 | — | New Alliance Capital | ↗ |
Growth signals
Latest recorded traffic for Zhengxu (Shanghai) Biotechnology is 1.5K monthly website visits, up 36.4% over the last three months. Zhengxu (Shanghai) Biotechnology's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Series A7 investors entered at this stage
Lilly Asia Ventures
Boyu Capital
TF Capital
New Alliance Capital
Zoo Capital
FuTeng Capital
HongShan
Other known investors3 additional known investors
ShanghaiTech University
University of Chinese Academy of Sciences
Wuhan University
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Zhengxu (Shanghai) Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Zhengxu (Shanghai) Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.